BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid TumorsBusiness Wire • 05/22/25
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation InnovationBusiness Wire • 05/14/25
Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices +Seeking Alpha • 05/12/25
Chinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings BeatBenzinga • 05/07/25
Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/07/25
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGeneBusiness Wire • 04/29/25
Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?Investors Business Daily • 04/24/25
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival BenefitBenzinga • 04/03/25
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development ProgramBusiness Wire • 04/03/25
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung CancerBusiness Wire • 03/31/25
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal CancerBenzinga • 03/04/25
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with ChemotherapyBusiness Wire • 03/04/25
BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/27/25
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesBusiness Wire • 02/27/25